805 related articles for article (PubMed ID: 27232512)
1. Novel approaches in cancer immunotherapy.
Subramaniam DS; Liu SV; Giaccone G
Discov Med; 2016 Apr; 21(116):267-74. PubMed ID: 27232512
[TBL] [Abstract][Full Text] [Related]
2. The current landscape of early drug development for patients with sarcoma in the immunotherapy era.
Sebio A; Wilky BA; Keedy VL; Jones RL
Future Oncol; 2018 May; 14(12):1197-1211. PubMed ID: 29699407
[TBL] [Abstract][Full Text] [Related]
3. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
Ă–zdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
[TBL] [Abstract][Full Text] [Related]
4. CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy.
Kranz LM; Beck JD; Grunwitz C; Hotz C; Vormehr M; Diken M
Hum Vaccin Immunother; 2017 Oct; 13(10):2272-2279. PubMed ID: 28846471
[No Abstract] [Full Text] [Related]
5. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.
Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W
Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548
[TBL] [Abstract][Full Text] [Related]
6. An overview of cancer immunotherapeutic strategies.
Wahid B; Ali A; Rafique S; Waqar M; Wasim M; Wahid K; Idrees M
Immunotherapy; 2018 Aug; 10(11):999-1010. PubMed ID: 30149763
[TBL] [Abstract][Full Text] [Related]
7. Current status and future prospects of peptide-based cancer vaccines.
Wada S; Yada E; Ohtake J; Fujimoto Y; Uchiyama H; Yoshida S; Sasada T
Immunotherapy; 2016 Nov; 8(11):1321-1333. PubMed ID: 27993087
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in immunotherapy for kidney cancer.
Ball MW; Allaf ME; Drake CG
Discov Med; 2016 Apr; 21(116):305-13. PubMed ID: 27232516
[TBL] [Abstract][Full Text] [Related]
9. Reversing T-cell Dysfunction and Exhaustion in Cancer.
Zarour HM
Clin Cancer Res; 2016 Apr; 22(8):1856-64. PubMed ID: 27084739
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint modulation: rational design of combination strategies.
Zamarin D; Postow MA
Pharmacol Ther; 2015 Jun; 150():23-32. PubMed ID: 25583297
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
12. Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors.
Aspeslagh S; Marabelle A; Soria JC; Armand JP
Chin Clin Oncol; 2015 Dec; 4(4):48. PubMed ID: 26730760
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in pancreatic cancer: New hope or mission impossible?
Jiang J; Zhou H; Ni C; Hu X; Mou Y; Huang D; Yang L
Cancer Lett; 2019 Mar; 445():57-64. PubMed ID: 30641107
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulation in cancer.
Hegmans JP; Aerts JG
Curr Opin Pharmacol; 2014 Aug; 17():17-21. PubMed ID: 25011112
[TBL] [Abstract][Full Text] [Related]
15. Clinical development of immunotherapy for prostate cancer.
Noguchi M; Koga N; Igawa T; Itoh K
Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
[TBL] [Abstract][Full Text] [Related]
16. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy as an Option for Cancer Treatment.
Rusch T; Bayry J; Werner J; Shevchenko I; Bazhin AV
Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):89-96. PubMed ID: 29026920
[TBL] [Abstract][Full Text] [Related]
18. Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets.
Kumar AR; Devan AR; Nair B; Vinod BS; Nath LR
Mol Biol Rep; 2021 Dec; 48(12):8075-8095. PubMed ID: 34671902
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial Cancer Immunotherapies.
Hellmann MD; Friedman CF; Wolchok JD
Adv Immunol; 2016; 130():251-77. PubMed ID: 26923003
[TBL] [Abstract][Full Text] [Related]
20. Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy.
Gao S; Yang D; Fang Y; Lin X; Jin X; Wang Q; Wang X; Ke L; Shi K
Theranostics; 2019; 9(1):126-151. PubMed ID: 30662558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]